-

ONCONASE maker announces move toward completion of IIIB mesothelioma clinical trials
Alfacell announced its third-quarter financial results with optimism about its chemotherapy drug Onconase, which is in the process of completing IIIB clinical trials for the treatment of inoperable mesothelioma, a rare form of cancer caused by asbestos exposure. In addition to progress on the clinical trial for mesothelioma, the company is also moving toward Phase

Alfacell announced its third-quarter financial results with optimism about its chemotherapy drug Onconase, which is in the process of completing IIIB clinical trials for the treatment of inoperable